Last $64.13 USD
Change Today +1.23 / 1.96%
Volume 364.1K
LGND On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/14/14 - $80.42
52 Week Low
05/6/13 - $25.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. Its late-stage development programs include Promacta, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Captisol-enabled Melphalan IV for the multiple myeloma transplant setting; Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis; and Nexterone, an injectable formulation. The company’s late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program for the treatment of Alzheimer’s disease; Captisol-enabled Carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings; and Captisol-enabled Delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections. It also offers Sparsentan that is in Phase II clinical trials for kidney diseases; Lasofoxifene, an estrogen partial agonist for osteoporosis treatment and other diseases; and Captisol-enabled Topiramate Injection, which is in Phase I clinical trials for the treatment of partial onset or primary generalized tonic-clonic seizures. In addition, the company’s preclinical stage products include HepDirect for liver diseases; Oral Human Granulocyte Colony Stimulating Factor for the treatment of Neutropenia; and IRAK4 Inhibitor for inflammation. Further, it provides Glucagon Receptor Antagonist that is in Phase I clinical trials for diabetes; Selective Androgen Receptor Modulator, which is in Phase II clinical trials for the therapeutic benefits; and Captisol-Enabled Clopidogrel that is in Phase III clinical trials for anti-coagulants. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.

20 Employees
Last Reported Date: 02/24/14
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $484.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $246.3K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $359.6K
Vice President, General Counsel and Secretary
Total Annual Compensation: $275.2K
Compensation as of Fiscal Year 2012.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Names Melanie J. Herman as Principal Accounting Officer

The board of directors of Ligand Pharmaceuticals Incorporated appointed Melanie J. Herman as the company's principal accounting officer. Ms. Herman, 35, currently serves as the company's director of accounting. She joined the company in January 2011 and served as the company's controller until her promotion to Director of Accounting in March 2014. Previously she was Controller at CyDex Pharmaceuticals Inc. from 2009 to 2011, Assistant Controller and Accounting Manager at Entertainment Properties Trust from 2004 to 2009, and Senior Accountant at KPMG, LLP from 2001 to 2004.

Ligand Completes Enrollment of Phase 1 Clinical Trial LGD-6972 for the Treatment of Type 2 Diabetes

Ligand announced that the Phase 1 clinical trial of its novel, oral glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes has completed enrollment, and that company plans to present data from that trial at the 74th American Diabetes Association Scientific Sessions meeting in June 2014.

Ligand Pharmaceuticals Incorporated Earns $1 Million Milestone Payment as a Result of FDA Approval of Merck's NOXAFIL(R) (Posaconazole) Injection

Ligand Pharmaceuticals Incorporated announced that it has earned a $1 million milestone payment as a result of the recent U.S. Food and Drug Administration approval of Merck's NOXAFIL(R) (posaconazole) injection (18 mg/mL). This is a new Captisol(R)-enabled formulation of NOXAFIL for intravenous (IV) use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement. NOXAFIL injection for intravenous use is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy. NOXAFIL injection is indicated in patients 18 years of age and older. The availability of a NOXAFIL formulation for intravenous administration is particularly important for those patients who may benefit from or require intravenous therapy, or who might not be able to take an oral formulation. Merck's antifungal agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $64.13 USD +1.23

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGND.
View Industry Companies

Industry Analysis


Industry Average

Valuation LGND Industry Range
Price/Earnings 100.0x
Price/Sales 26.8x
Price/Book 26.5x
Price/Cash Flow 115.8x
TEV/Sales 26.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at